Find in Library
Search millions of books, articles, and more
Indexed Open Access Databases
A Pilot Study to Assess the Feasibility of the Spanish Diabetes Self-Management Program in the Basque Country
oleh: Estibaliz Gamboa Moreno, Lourdes Ochoa de Retana Garcia, Maria Emma del Campo Pena, Álvaro Sánchez Perez, Catalina Martinez Carazo, Juan Carlos Arbonies Ortiz, Maria Angeles Rua Portu, Koldo Piñera Elorriaga, Amaya Zenarutzabeitia Pikatza, Miren Nekane Urquiza Bengoa, Tomás Méndez Sanpedro, Ana Oses Portu, Lourdes Gorostidi Fano, Miren Bakarne Aguirre Sorondo, Kalliopi Vrotsou, Rafael Rotaeche Del Campo
Format: | Article |
---|---|
Diterbitkan: | Wiley 2016-01-01 |
Deskripsi
Purpose. The purpose of this study was to assess the feasibility of the Spanish Diabetes Self-Management Program (SDSMP) in the primary care setting of the Basque Health Service and offer initial estimations of the randomized controlled trial (RCT) effects. Methods. Ten health centers (HCs) participated in a single-arm pilot study with a 6-month follow-up period between February 2011 and June 2012. Recruitment was performed via invitation letters, health professionals, and the local media. Each intervention group consisted of 8–15 people. The ability of each HC in forming up to 2 groups, participants’ compliance with the course, and coordination and data collection issues were evaluated. Glycated haemoglobin (HbA1c) was the main outcome variable. Secondary outcomes were cardiovascular risk factors, drugs consumption, medical visits, quality of life, self-efficacy, physical exercise, and diet. Results. Two HCs did not organize a course. A total of 173 patients initiated the program, 2 dropped out without baseline data, and 90% completed it. No pre-post HbA1c differences existed. Certain improvements were observed in blood pressure control, self-efficacy, physical activity, and some dietary habits. Conclusion. The SDSMP is feasible in our setting. Our experience can be of interest when planning and conducting this program in similar health settings. The trial is registered with ClinicalTrials.gov identifier NCT01642394.